IMPROVING THE MEDICAL ABORTION REGIMEN


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To determine the medical and social characteristics of women undergoing termination of pregnancy earlier than 6 weeks and to comparatively evaluate the efficacy and safety of different mifepristone doses for medical abortion (МА). Subjects and methods. A prospective comparative study of the efficacy of different mifepristone doses (600 and 200 mg) for a MA regimen was conducted in 337 and 130 women undergoing termination pregnancy less than 6 weeks’ gestation, respectively. Sonography, vaginal smear bacterioscopy, and in some cases, if indicated, vacuum aspiration, pathomorphological examination of the uterine material were performed. Results. The medico-social portrait of women preferring a reduced mifepristone dose is presented with their late reproductive age (35-43 years), blue-collarjobs, unemployed, mainly legally married women, and parous women who had fewer artificial abortions and a history of MA. Previous genital inflammatory diseases and reproductive losses were determinants in women who are a group at high-risk for post-abortion infectious complications (incomplete abortion and endo-metritis), However, the frequency of complications of MA did not depend on the used dose of mifepristone. The low frequency of complications of MA was ascertained to be associated with a package of preventive measures, such as sanitation of the lower genital tract, ultrasound monitoring of the quality of an abortion.

全文:

受限制的访问

作者简介

E. PLOTKO

Ural State Medical Academy; «Harmony» Medical Center

Email: plotko@g-mc.ru

参考

  1. Jones R.K., Kooistra K. Abortion incidence and access to services in the United States, 2008. Perspect. Sex. Reprod. Health. 2011; 43(1): 41-50.
  2. Raymond E.G., Shannon C., Weaver M.A., Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception. 2013; 87(1): 26-37.
  3. Winikoff B., Sheldon W. Use of medicines changing the face of abortion. Int. Perspect. Sex. Reprod. Health. 2012; 38(3): 164-6.
  4. Dalvie S. Secretariat, Asia Safe Abortion Partnership, Mumbai, India, personal communication. July 2, 2012.
  5. Ngoc N.T., Blum J., Raghavan S., Nga N.T., Dabash R., Diop A., Winikoff B. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception. 2011; 83(5): 410-7.
  6. World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: World Health Organization; 2012.
  7. Schaff E.A., Fielding S.L., Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002; 66(4): 247-50.
  8. Chawdhary R., Rana A., Pradhan N. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasirandomized controlled trial. J. Obstet. Gynaecol. Res. 2009; 35(1): 78-85.
  9. Boersma A.A., Meyboom-de Jong B., Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curagao. Eur. J. Contracept. Reprod. Health Care. 2011; 16(2): 61-6.
  10. Chong E., Tsereteli T., Nguyen N.N., Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception. 2012; 86(3): 251-6.
  11. Fernandez M.M., Coeytaux F., de Leon R.G., Harrison D.L. Assessing the global availability of misoprostol. Int. J. Gynaecol. Obstet. 2009; 105(2): 180-6.
  12. Kulier R., Kapp N., Gtilmezoglu A.M., Hofmeyr G.J., Cheng L., Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev. 2011; (11): CD002855.
  13. Lievre M., Sitruk-Ware R. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception. 2009; 80(1): 95-100.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2013
##common.cookie##